Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents
Table 2
Mean values and SD of clinical and laboratory parameters in relation to total assessments and nutritional status.
Parameter
Total
Eutrophic
Overweight
Obese
Prescribed dose% (mg/day)
2.1 ± 1.3
2.0 ± 1.3
2.4 ± 1.3
2.1 ± 1.4
0.250
Adjusted dose%% (mg/Kg)
0.04 ± 0.03
0.05 ± 0.03
0.04 ± 0.02
0.03 ± 0.02
0.343
Time used (months)
25.9 ± 27.2
24.7 ± 27.6
29.0 ± 27.0
27.4 ± 24.9
0.369
Age (years)
13.0 ± 3.1
12.9 ± 2.9
13.5 ± 3.6
10.7 ± 3.1
0.176
Bone age (years)
13.0 ± 3.1
13.0 ± 3.1
13.3 ± 3.2
10.9 ± 3.0
0.305
WC (cm)
75.4 ± 11.5
70.8 ± 9.3
<0.001
SBP (mmHg)
102.5 ± 11.8
100.6 ± 10.3
108 ± 21.7
0.080
DBP (mmHg)
63.5 ± 11.3
62.1 ± 11.1
62 ± 14.8
0.078
Glycemia (mg/mL)
85.2 ± 8.5
84.2 ± 7.7
86.7 ± 8.5
93.6 ± 15.0
0.120
Insulin (nUI/mL)
9.4 ± 9.8
7.5 ± 8.3
10.1 ± 8.1
0.003
HOMA-IR index
2.0 ± 2.3
1.6 ± 2.1
2.5 ± 2.0
0.002
Total cholesterol (mg/dL)
156.2 ± 35.9
151.4 ± 31.2
164.0 ± 43.7
184.6 ± 40.7
0.096
LDL cholesterol (mg/dL)
87.5 ± 29.1
82.8 ± 26.2
107.0 ± 31.1
0.045
HDL cholesterol (mg/dL)
52.7 ± 14.1
53.9 ± 14.9
48.7 ± 12.0
57.4 ± 5.9
0.119
Triglycerides (mg/dL)
80.3 ± 45.4
73.9 ± 38.6
93.5 ± 56.8
101.0 ± 55.7
0.081
AST (U/L)
23.4 ± 10.0
23.4 ± 10.9
22.8 ± 6.7
28.2 ± 12.4
0.475
ALT (U/L)
18.4 ± 16.9
16.5 ± 17.0
31.4 ± 33.0
0.001
Leptin (pg/mL)
26.0 ± 16.4
19.2 ± 12.7
<0.001
WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure. Kruskal-Wallis test. Statistically significant difference (by Mann-Whitney test) between overweight and normal weight. Statistically significant difference (by Mann-Whitney test) between obese and normal weight individuals (). %Total prescribed risperidone. %%Prescribed dose of risperidone, but adjusted per kg of body weight.
